Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer

By sjmartinez • October 22, 2022

Makrakis D, Talukder R, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Grant M, Lythgoe MP, Pinato DJ, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Di Lorenzo G, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Yu EY, Wright JL, Grivas P, Khaki AR. Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer. BJU Int. 2022 Nov;130(5):592-603. doi: 10.1111/bju.15603. Epub 2021 Oct 25. PMID: 34597472.

Tags: BladderCancer, blcsm, Hematology/Oncology, immune checkpoint, immunotherapy, inhibitors, Outcomes, Publications, urinary tract neoplasms, uroonc, urothelial carcinoma, utuc

CD146+ pericyte-like lung cancer brain metastatic stem cells promote tumor angiogenesis through dual regulatory effects on the VEGF/VEGFR axis

Liu W, Duan W, Xia S, Liu Y, Chu H, Liang K, Fang S, Lin M, Wei S, You X, Hu Q, Qi J, Wang[...]

Phosphatidylserine receptors TIM-1 and AXL mediate tick-borne Powassan virus entry

Daskou M, Zaiss AK, Jeyachandran AV, Takano KA, Kan RL, Paravastu R, Gerald E, Satheeshkumar N, Rios-Rodriguez J, Russell B, Brault AC, Bhaduri A, Garcia[...]

Replication-Competent, Tumor-Specific Immuno-Gene Vectors Allow for Exchange of Transgenes and Lead to Viral Persistence Following IV Administration

Rosen LS, Ottensmeier C, Hawkins M, Naing A, Sonpavde G, Van Tine BA, Parkes EE, O'Cathail SM, Ji RR, Thomas M, Stacey A, Sasso MS,[...]